Skip to content
Screener

Replimune Group REPL Current ratio

Current ratio at other companies

Amgen logo
AmgenAMGN
1.4×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.3×-1.3×
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
28×+23.4×
Regenxbio logo
RegenxbioRGNX
2.9×-0.3×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
CG Oncology logo
CG OncologyCGON
22.2×+0.1×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on the most recent quarter.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026. Open the filing →

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805

FAQ

What is Replimune Group's current ratio?
Replimune Group (REPL) reported current ratio of 5.6× in Q4 2025.
How has Replimune Group's current ratio changed year-over-year?
Replimune Group's current ratio decreased by 51.0% year-over-year, from 11.4× to 5.6×.
What is the long-term trend for Replimune Group's current ratio?
Over 4 years (2021 to 2025), Replimune Group's current ratio has grown at a -30.1% compound annual growth rate (CAGR), from 33.3× to 8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Replimune Group's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude